Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?

Acute myeloid leukemia (AML) is a myeloid malignancy carrying a heterogeneous molecular panel of mutations participating in the blockade of differentiation and the increased proliferation of myeloid hematopoietic stem and progenitor cells. The historical “3 + 7” treatment (cytarabine and daunorubici...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, Solène, Desplat, Vanessa, Villacreces, Arnaud, Guitart, Amélie V., Milpied, Noël, Pigneux, Arnaud, Vigon, Isabelle, Pasquet, Jean-Max, Dumas, Pierre-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679203/
https://www.ncbi.nlm.nih.gov/pubmed/31336846
http://dx.doi.org/10.3390/ijms20143429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679203/
https://www.ncbi.nlm.nih.gov/pubmed/31336846
http://dx.doi.org/10.3390/ijms20143429

Ejemplares similares